Recent News

• 04.10.2025 - Inozyme’s No-Cost Genetic Testing Program for ENPP1 and ABCC6 Deficiencies
• 04.10.2025 - PROPEL Study Fact Sheet
• 04.10.2025 - Novel Radiographic Features of Pediatric ENPP1 Deficiency
• 04.10.2025 - Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency
• 04.07.2025 - April 7, 2025 2:15 PM EDT - April 7, 2025 2:55 PM EDT : 24th Annual Needham Virtual Healthcare Conference
• 03.31.2025 - Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference
• 03.10.2025 - Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights
• 03.03.2025 - March 3, 2025 1:10 PM EST - March 3, 2025 1:40 PM EST : TD Cowen 45th Annual Health Care Conference
• 02.26.2025 - Senior Director Medical and Safety
• 02.24.2025 - Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference

Recent Filings

• 04.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.17.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.17.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.17.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.10.2025 - EX-99.1 EX-99.1
• 03.10.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.10.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.10.2025 - 8-K Current report